In patients with an atypical non-amnestic presentation, the diagnosis of AD is possible by using pathophysiological biomarkers such as cerebrospinal fluid (CSF) biomarkers or amyloid/tau positron emission tomography (PET) imaging. The gene discussed is MAPT; the disease is Alzheimer disease.